These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1134 related articles for article (PubMed ID: 25616671)
21. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335 [TBL] [Abstract][Full Text] [Related]
22. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810 [TBL] [Abstract][Full Text] [Related]
23. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence. Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718 [TBL] [Abstract][Full Text] [Related]
24. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients. Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739 [TBL] [Abstract][Full Text] [Related]
25. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Bagust A; Greenhalgh J; Boland A; Fleeman N; McLeod C; Dickson R; Dundar Y; Proudlove C; Shaw R Pharmacoeconomics; 2010; 28(6):439-48. PubMed ID: 20465313 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. Auvray M; Tougeron D; Auclin E; Moulin V; Artru P; Hautefeuille V; Hammel P; Lecomte T; Locher C; Sickersen G; Coriat R; Lecaille C; Vernerey D; Taieb J; Pernot S Clin Colorectal Cancer; 2020 Mar; 19(1):39-47.e5. PubMed ID: 31648924 [TBL] [Abstract][Full Text] [Related]
27. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer. Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616 [TBL] [Abstract][Full Text] [Related]
28. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. Shi Y; Wan X; Tan C; Li J; Peng L Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066 [TBL] [Abstract][Full Text] [Related]
29. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000 [TBL] [Abstract][Full Text] [Related]
30. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin. Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749 [TBL] [Abstract][Full Text] [Related]
31. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Tappenden P; Jones R; Paisley S; Carroll C Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499 [TBL] [Abstract][Full Text] [Related]
32. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581 [TBL] [Abstract][Full Text] [Related]
33. Aflibercept: A Review in Metastatic Colorectal Cancer. Syed YY; McKeage K Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913 [TBL] [Abstract][Full Text] [Related]
34. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543 [TBL] [Abstract][Full Text] [Related]
35. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670 [TBL] [Abstract][Full Text] [Related]
36. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113 [TBL] [Abstract][Full Text] [Related]
37. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A; Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906 [TBL] [Abstract][Full Text] [Related]
38. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685 [TBL] [Abstract][Full Text] [Related]
39. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer]. André T; Chibaudel B Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539 [TBL] [Abstract][Full Text] [Related]